Rosario, SANTA%20FE%20PROVINCE1 Active Studies

Myasthenia Gravis Clinical Trials in Rosario, SANTA%20FE%20PROVINCE

Find 1 actively recruiting myasthenia gravis clinical trials in Rosario, SANTA%20FE%20PROVINCE. Connect with local research sites and explore new treatment options.

1
Active Trials
1
Sponsors
264
Enrolling

Recruiting Myasthenia Gravis Studies in Rosario

About Myasthenia Gravis Clinical Trials in Rosario

Myasthenia gravis is a chronic autoimmune neuromuscular disease that causes weakness in the skeletal muscles responsible for breathing and movement. It occurs when communication between nerves and muscles is disrupted. Treatment includes medications that improve neuromuscular transmission and immunosuppressive therapies.

There are currently 1 myasthenia gravis clinical trials recruiting participants in Rosario, SANTA%20FE%20PROVINCE. These studies are seeking a combined 264 participants. Research is being sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany. Clinical trial participation is free and participants receive study-related medical care at no cost.

Myasthenia Gravis Clinical Trials in Rosario — FAQ

Are there myasthenia gravis clinical trials in Rosario?

Yes, there are 1 myasthenia gravis clinical trials currently recruiting in Rosario, SANTA%20FE%20PROVINCE. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Rosario?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Rosario research site will contact you about next steps.

Are clinical trials in Rosario free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Rosario studies also compensate for your time and travel.

What myasthenia gravis treatments are being tested?

The 1 active trials in Rosario are testing new therapies including novel drugs, biologics, and treatment approaches for myasthenia gravis.

Data updated March 2, 2026 from ClinicalTrials.gov